According to the ETF Finder at ETF Channel, INCY makes up 2.53% of the Dynamic Biotechnology & Genome Portfolio ETF (PBE) which is higher by about 1.4% on the day Thursday.
In afternoon trading Thursday, INCY was up about 5.1% on the day.
For as much as we love and respect you, Gilead, the current situation is unacceptable. The once great and mighty biotech Gilead cannot trade at a 6x forward earnings multiple!
Investors have convinced themselves that President Donald Trump is going to make drug stocks great again. Will it last?